1KA Stock Overview
Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
GH Research PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.50 |
| 52 Week High | US$19.50 |
| 52 Week Low | US$5.65 |
| Beta | 0.86 |
| 1 Month Change | 11.76% |
| 3 Month Change | -37.91% |
| 1 Year Change | -12.04% |
| 3 Year Change | -12.04% |
| 5 Year Change | n/a |
| Change since IPO | -34.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1KA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 21.0% | 2.2% | 2.5% |
| 1Y | -12.0% | -17.6% | 13.4% |
Return vs Industry: 1KA exceeded the German Pharmaceuticals industry which returned -15.5% over the past year.
Return vs Market: 1KA underperformed the German Market which returned 15% over the past year.
Price Volatility
| 1KA volatility | |
|---|---|
| 1KA Average Weekly Movement | 12.2% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 1KA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1KA's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 50 | Villy Valcheva | www.ghres.com |
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders.
GH Research PLC Fundamentals Summary
| 1KA fundamental statistics | |
|---|---|
| Market cap | €609.63m |
| Earnings (TTM) | -€34.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-16.1x
P/E RatioIs 1KA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1KA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$38.96m |
| Earnings | -US$38.96m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1KA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 08:19 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GH Research PLC is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Jason Butler | Citizens JMP Securities, LLC |